Europe’s Landmark Psychedelic Medicine Gathering Returns to London
Prohibition Partners, a global data and events company for emerging industries, and Drug Science, a leading UK charity and advocacy group, are proud to announce PSYCH Symposium 2025, to be held at London’s Kings Place on November 19, 2025.
After two sold-out editions in 2022 and 2023, PSYCH Symposium has become the landmark European gathering for thought leaders in the emerging field of psychedelic medicine—one of the fastest-growing and most promising fields in mental health.
Key figures in science, healthcare, investment, and policy will meet in London for an international conference dedicated to sharing research, discussing policy and improving access to psychedelic medicine. Mental health disorders such as depression, anxiety, PTSD, and addiction affect hundreds of millions worldwide. Conventional treatments, while helpful for many, often fall short, leaving an urgent need for innovation.
Psychedelic-assisted therapies are emerging as a powerful alternative, supported by a growing body of clinical research. Substances such as psilocybin, MDMA, and ketamine have demonstrated the potential to provide rapid, long-lasting relief for patients where traditional treatments have failed.
Prof. David Nutt, Professor of Neuropsychopharmacology at Imperial College London and Chair of Drug Science, said:
"We are amid a mental health crisis and our current treatments are failing millions. This event is critical because it shifts the dialogue on psychedelics from anecdote to evidence, offering a tangible pathway to what could be the most significant breakthrough in mental healthcare in half a century."
The 2025 edition of PSYCH Symposium is a collaboration between Prohibition Partners and Drug Science. The two organisations collectively bring forward decades of expertise as trusted platforms for discussing policy, science and investment in the emerging field of psychedelic medicine.
The event will bring together clinicians, researchers, policymakers, investors, and patient advocates to discuss:
The latest clinical findings on psilocybin, MDMA, ketamine, and other emerging compounds
The business and investment landscape for psychedelic medicines
Policy frameworks and regulatory updates across Europe and globally
Ethical considerations and patient safety in psychedelic-assisted therapies
"While other events discuss the global potential, this symposium is uniquely focused on building a responsible and effective framework for the United Kingdom. It's where policymakers, clinicians, and investors will convene to design the future of psychedelic medicine within the NHS and the UK's specific regulatory environment," said Professor Nutt.
The event’s roster includes some of the most influential speakers and companies in the space, including:
Professor David Nutt, Professor of Neuropsychopharmacology at Imperial College London and Chair of Drug Science.
Nige Netzband, Founder of Athletes Journey Home UK
Matthew Wall, Head of MRI applications at Invicro, LLC
PSYCH Symposium 2025 will spotlight new data, clinical delivery models, and equitable access strategies.
Attendees can expect high-quality networking opportunities, in-depth discussions, and a focused environment conducive to meaningful collaboration among key stakeholders in the psychedelic medicine ecosystem.
The Psychedelic Opportunity
The psychedelic medicine market is entering a period of rapid growth, reflecting both scientific breakthroughs and rising global demand for new mental health solutions. Worldwide, the industry is projected to expand from today’s early stage to between $3.8–4.6 billion by 2030, with some forecasts suggesting as high as $7–10 billion by the early 2030s.
Europe is poised to play a central role in this expansion: the regional market alone is expected to grow from $340 million in 2024 to nearly $880 million by 2032.
Why London?
London is a global hub for medical research, investment, and policymaking. It brings together world-leading universities, hospitals, and innovators driving psychedelic science forward. Its central location, diverse community, and progressive dialogue on mental health position it at the forefront of Europe’s psychedelic medicine industry.
Stephen Murphy, Founder & CEO of Prohibition Partners and PSYCH Symposium, said:
“Over the past three years, PSYCH Symposium has become the focal point for Europe’s psychedelic medicine sector, bringing together investors, regulators, researchers and clinical leaders. We have hosted many of the most respected voices in science, healthcare and policy, creating a unique environment for advancing serious conversations and real progress. London continues to lead from the front. With world-class research institutions, a vibrant investment community and a growing demand for innovative mental health solutions, the UK is firmly at the centre of this rapidly evolving global movement.”
"Our partnership with Prohibition Partners is vital. It ensures our mission is grounded not just in scientific excellence, but in commercial and regulatory reality," said Professor Nutt.
Tickets for the limited-capacity event are available now. PSYCH Symposium is supported by Psychedelic Health as a key media partner.
Contact Details
31 New Inn Yard
Shoreditch
EC2A 3EY
United Kingdom
info@psychsymposium.com
About Prohibition Partners
Prohibition Partners is the leading connector for the global cannabis and psychedelics industries.
Through market intelligence, media, events, and digital commerce, we help businesses identify opportunities, make informed decisions, and build lasting commercial relationships.
Founded in 2017, Prohibition Partners has built a portfolio of trusted brands shaping the future of these markets. Our flagship events, Cannabis Europa and Business of Cannabis in London, New York, and Berlin, bring together operators, investors, and policymakers, while PSYCH Symposium convenes global leaders in psychedelic medicine. Our publications and media platforms, including The European Cannabis Report, The Global Cannabis Report, Business of Cannabis, Cannabis Health, and Psychedelic Health, are among the most widely read and cited sources of insight and analysis in the sector. Extending beyond intelligence and media, we also operate Atalis, a new B2B marketplace enabling cannabis businesses across Europe and beyond to buy and sell products and services seamlessly.
About Drug Science
Drug Science is the only completely independent, science-led drugs charity in the UK, uniquely bringing together leading drugs experts from a wide range of specialisms to carry out ground-breaking research into drug harms and effects. Drug Science works to provide an evidence base free from political or commercial influence, creating the foundation for sensible and effective drug laws, and equipping the public, media and policy makers with the knowledge and resources to enact positive change.